Skip to content

Cyril Amarchand Mangaldas is acting as principal counsel to MPS Limited on USD 16.5 Million Acquisition of Unbound Medicine

The transaction involves a 100% stock purchase and strengthens MPS’s global footprint in digital healthcare solutions.

By
Content reader

Listen to this article

Ready to read this article aloud.
Cyril Amarchand Mangaldas is acting as principal counsel to MPS Limited on USD 16.5 Million Acquisition of Unbound Medicine

Cyril Amarchand Mangaldas (“CAM“) is acting as principal counsel to MPS Limited, a public limited company listed on Indian stock exchange and its subsidiary, MPS North America LLC (the “Purchaser“), in relation to the acquisition of 100% of the issued and outstanding capital stock of Unbound Medicine, Inc. (the “Company”) pursuant to a stock purchase agreement executed among the Company, the Purchaser, William M. Detmer, and certain stockholders of the Company, for an aggregate consideration of USD16,500,000, subject to customary adjustments. The Company is engaged in the business of healthcare and medical information technology.

The transaction was led by Mohit Gogia, Partner; with support from Anisha Dash, Senior Associate; and Muskaan Garg, Swathi Kathi, Avikalp Mishra, and Yash Kataria, Associates.

WhatsApp LinkedIn

0 replies

Leave a Reply

Your email address will not be published. Required fields are marked *.

This site uses Akismet to reduce spam. Learn how your comment data is processed.